Dendreon Execs Sued Over Sunny Cancer Drug Sales Forecasts
Dendreon Corp.'s executives have been hit with a shareholder derivative suit accusing them of withholding details about marketing issues concerning the firm's prostate cancer drug Provenge and causing a 67 percent...To view the full article, register now.
Already a subscriber? Click here to view full article